MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (Nasdaq: MLTX) is hosting its Capital Markets Day in New York, featuring a live webcast for virtual attendees. The event runs from 10:30-12:30 EDT and includes presentations from the executive team discussing a financial update, near-term catalysts, and the company’s publication roadmap.
The focus will be on sonelokimab, a novel investigational Nanobody® targeting inflammatory diseases, along with an update from Professor Kenneth B. Gordon on treatment landscapes following the AAD Annual Meeting. Top-line results for sonelokimab’s Phase 2 trial in hidradenitis suppurativa are anticipated by June 2023, with additional trials in psoriatic arthritis ongoing.
- None.
- None.
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host today its Capital Markets Day for investors and analysts in New York and virtually.
The live event will be held in New York, US, with a webcast available for virtual attendees, from 10:30-12:30 EDT (15:30-17:30 BST / 16:30-18:30 CEST). Register for the event and webcast here.
The event will feature a series of presentations from its executive team who will provide a financial update and look to the year ahead at near-term catalysts and the Company’s publication roadmap. The program follows the release of important competitor data, as presented at the recent American Academy of Dermatology (AAD) Annual Meeting, and will highlight the Company's lead candidate, sonelokimab a novel investigational Nanobody® for the treatment of inflammatory disease including providing a clinical trial progress update.
In addition, external speaker Professor Kenneth B. Gordon, Chair of Dermatology at the Medical College of Wisconsin, will provide an update on the treatment landscape and pipeline, reflecting on data and key takeaways from AAD which took place in March.
A Q&A session will follow the presentations.
Top-line results for a Phase 2 trial of sonelokimab in moderate-to-severe hidradenitis suppurativa are expected around the end of June 2023 with final read-out by Q4 2023. Patient enrollment in a global Phase 2 trial in psoriatic arthritis is on schedule with primary end-point readout expected at the end of 2023.
Additional details will be available on the Events & Presentations section of the Company’s website at www.ir.moonlaketx.com.
- Ends -
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.
About Nanobodies®
Nanobodies® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and the ability to design multivalent therapeutic molecules with bespoke target combinations.
About Sonelokimab
Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema.
Sonelokimab has been assessed in a randomized, placebo-controlled Phase 2b study in 313 patients with moderate-to-severe plaque-type psoriasis. Sonelokimab demonstrated a rapid and durable clinical response (Investigator’s Global Assessment Score 0 or 1, Psoriasis Area and Severity Index 90/100) in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).
In an earlier Phase 1 study in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196–203). Recently, a global phase 2 trial in psoriatic arthritis (NCT05640245, M1095-PSA-201, “ARGO”) including multiple arms and over 200 patients has been initiated (announced on Dec 14, 2022).
Sonelokimab is not yet approved for use in any indication.
Cautionary Statement Regarding Forward Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for clinical trials and research and development programs; and the anticipated timing of the results from those trials, including completing the MIRA trial; and the anticipated markets for products, if approved. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.
Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with MoonLake’s business in general and limited operating history, difficulty enrolling patients in clinical trials, and reliance on third parties to conduct and support its clinical trials, and the other risks described in or incorporated by reference into MoonLake’s Current Report on Form 8-K filed on April 11, 2022 and subsequent filings with the Securities and Exchange Commission.
Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.
MoonLake Immunotherapeutics Investors
Matthias Bodenstedt, CFO
info@moonlaketx.com
MoonLake Immunotherapeutics Media
Patricia Sousa
media@moonlaketx.com
Consilium Strategic Communications
Matthew Cole, Mary-Jane Elliott, Ashley Tapp
Tel: +44 (0) 20 3709 5700
media@moonlaketx.com
MoonLake@consilium-comms.com
FAQ
What is the purpose of MoonLake Immunotherapeutics' Capital Markets Day on April 19, 2023?
What key updates will be provided at the Capital Markets Day for MLTX?
When are the top-line results for sonelokimab's Phase 2 trial expected?
What is sonelokimab and what does it target?
What is the significance of the recent American Academy of Dermatology (AAD) Annual Meeting for MLTX?
What is the focus of MoonLake Immunotherapeutics as a clinical-stage biotechnology company?
